Puvida Wart Removal System

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts. Common warts are characterized by a rough, "cauliflower-like" surface and are easily recognizable. Plantar warts are specifically located on the soles of the feet, are tender to touch, and exhibit an interrupted footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes. After soaking, the area must be dried completely.

A sufficient amount of the medication should be applied using a cotton swab to ensure complete coverage of each wart. It is important to allow the application to dry fully. This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use is contraindicated in the following situations:

Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition.

The product should not be applied to moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes, as these areas may be sensitive or require specialized treatment.

Additionally, use is contraindicated in patients with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

Warnings and Precautions

For external use only. This product is contraindicated for application on irritated skin or any area that exhibits signs of infection or redness. It should not be applied to moles, birthmarks, or warts that have hair growing from them, nor should it be used on genital warts or warts located on the face or mucous membranes.

Patients with diabetes or those who have poor blood circulation should refrain from using this product due to the increased risk of adverse effects.

In the event of accidental ingestion, immediate medical assistance should be sought by contacting the Poison Control Center at 1-800-222-1222.

If discomfort persists after use, it is imperative to discontinue application and consult a healthcare professional for further evaluation and guidance.

Side Effects

For external use only. Patients are advised to stop use and consult a doctor if discomfort persists. This recommendation is crucial to ensure the safety and well-being of individuals using the product.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Puvida Wart Removal System (salicylic acid 17% wart removal system). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients should be advised against the use of this product on moles, birthmarks, warts with hair growing from them, genital warts, or warts on the face or mucous membranes due to the potential for adverse effects. Additionally, caution is warranted for women with diabetes or poor blood circulation, as these conditions may increase the risk of complications. The safety of this product during pregnancy has not been established, and healthcare professionals should weigh the potential risks against the benefits when considering its use in pregnant patients.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

There is no specific information regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may arise from an overdose. Common symptoms may include, but are not limited to, severe drowsiness, confusion, respiratory distress, or any other unusual clinical manifestations.

Management of an overdose should be tailored to the individual patient and may involve supportive care, symptomatic treatment, and, if appropriate, the use of specific antidotes. It is crucial to consult local poison control guidelines and the product's prescribing information for detailed management protocols.

In all instances of suspected overdose, healthcare professionals should ensure that the patient is stabilized and that appropriate interventions are initiated promptly.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center at 1-800-222-1222 if the product is swallowed. It is important to instruct patients not to apply the product on irritated skin or any areas that are infected or reddened.

Patients should be informed that the product is not intended for use on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Additionally, healthcare providers should caution patients against using the product if they have diabetes or poor blood circulation.

Patients should be advised to discontinue use and consult a doctor if discomfort persists. It is also essential to instruct patients to avoid contact with the eyes; if the product does come into contact with the eyes, they should flush the eyes with water for 15 minutes.

Finally, healthcare providers should remind patients that the product is non-edible, and they should ensure that the cap is tightly closed and the product is stored at room temperature, away from heat sources.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that it is kept away from excessive heat, specifically temperatures exceeding 37°C (99°F). Proper storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

Patients should be advised to avoid contact with the eyes when using the product. In the event of accidental exposure to the eyes, it is recommended to flush with water for 15 minutes. The product is non-edible, and patients should ensure that the cap is tightly secured and that it is stored at room temperature, away from heat sources.

Drug Information (PDF)

This file contains official product information for Puvida Wart Removal System, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)